SACRAMENTO, Calif. - TelAve -- Sacramento, CA  —  IGH Naturals, a leader in innovative hydration and recovery solutions, has begun enrollment of patients in a clinical trial evaluating the efficacy of its flagship product, Humolyte®, in alleviating common and debilitating side effects experienced by chemotherapy patients. The study is being conducted by a clinical research organization in India with multiple clinical sites and hospitals participating.

The study, which has received all necessary regulatory approvals, will enroll approximately 38 patients undergoing chemotherapy treatment. Most of these patients are at a high risk for developing mucositis (oral ulcers) from the chemotherapy. The study's primary focus is to assess Humolyte's ability to reduce symptoms of gastrointestinal distress including diarrhea, vomiting, as well as minimization of the severity of oral mucositis (mouth sores)—symptoms that frequently compromise patient comfort, hydration, and quality of life.

More on TelAve News

• Colbert Packaging Invites Visitors to Booth #N-5476 at PACK EXPO
• Men's Health Network Launches 2025 Prostate Cancer Awareness Month Campaign:
• Nashville International Chopin Competition Reflects on Global Summer, Unveils Fall & Winter Programs
• Phinge Invites Global Social Media Platforms & Major Brands To Join Netverse App-less Verified Platform To Reward & Safeguard Their Users & Customers
• Next-Generation Website Launch Highlights New Growth Phase Including $10 Million Acquisitions Plan for AI Powered Sports, Entertainment, Gaming Leader

In addition to symptom relief, the trial will also evaluate Humolyte's potential to reduce the need for frequent intravenous (IV) hydration in chemotherapy patients, a breakthrough that could significantly enhance patient convenience and reduce healthcare costs.

"We are committed to advancing supportive care in oncology and currently, there are no effective solutions in the market that can reduce the symptoms of mucositis while enhancing hydration of these patients at home," said Dr. Sourabh Kharait, the Founder and CEO of IGH Naturals. "This study represents an important step in validating Humolyte as a safe, effective, and patient-friendly solution for managing chemotherapy-related complications."

The trial is expected to generate critical data on both the efficacy and tolerability of Humolyte, helping to inform future treatment protocols and improve overall patient outcomes. The study is expected to complete enrollment by spring of 2026.

For more information about the study or HuMOLYTE's commitment to innovative patient care solutions, please visit [www.humolyte.com] or contact: